Phenotypes Associated with This Genotype

Genotype
MGI:6198665

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-MFN2*T105M)Dple}/Gt(ROSA)26Sor⁺; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:251584 )

• mice develop a diseased phenotype beginning 4-6 weeks following tamoxifen treatment, with multiple organ failure leading to lethality

respiratory system

respiratory distress ( J:251584 )

• mice develop respiratory distress 4-6 weeks after tamoxifen treatment

behavior/neurological

abnormal motor capabilities/coordination/movement ( J:251584 )

• mice exhibit loss of mobility 4-6 weeks after tamoxifen treatment

cellular

abnormal mitochondrial morphology ( J:251584 )

• tamoxifen-treated mice exhibit mitochondrial aggregation in renal cortex and liver parenchyma and small mitochondria aggregation in Schwann cell cytoplasm of the sciatic nerve, most likely indicating un-fused mitochondria

homeostasis/metabolism

ascites ( J:251584 )

• mice develop bloating due to ascites accumulation 4-6 weeks after tamoxifen treatment

integument

abnormal hair follicle morphology ( J:251584 )

• mice exhibit skin follicle erection 4-6 weeks after tamoxifen treatment

nervous system

abnormal myelination ( J:251584 )

• tamoxifen-treated mice show abnormal myelination of the tibial nerve, with abnormal myelin configurations surrounding some axons

• tibial nerves of tamoxifen-treated mice show double myelinated axons in which the inner portion of the outer sheath is decompacting